Catalent Is Linked to Regeneron’s Eye-Drug Rejection in Latest Misstep
Problems at a Catalent Inc. production facility led US regulators to deny a key drug application from Regeneron Pharmaceuticals Inc., the latest headache for one of the main manufacturing partners to the drug industry. • None UBS Preparing to Cut Over Half of Credit Suisse Workforce The Food and…
#catalentinc #noneubs #regeneron #eylea #bloomington #indiana #fda #catalent #modernaincs #novonordiskas